Here's what we'll cover
Here's what we'll cover
If you've been sticker-shocked by the cost of Ozempic, you're not alone. And a new decision from Maryland's Drug Affordability Board (MDAB) is drawing national attention as a potential turning point in how states fight back against high GLP-1 prices.
Here's what actually happened, what it means in practical terms, and what you can do right now regardless of where you live.
What Maryland's Drug Affordability Board Actually Did
The Maryland Drug Affordability Board is a state agency with a specific, powerful mandate: set upper payment limits (UPLs) on prescription drugs when prices are deemed unaffordable for state residents and payers.
In May 2025, the board voted to set a payment limit on Ozempic, the brand-name version of semaglutide made by Novo Nordisk. This means that for certain payers operating under Maryland's authority, there is now a ceiling on what they can be required to pay per dose or per prescription fill.
This is significant because Maryland is one of the few states in the country with the legal infrastructure to actually enforce these kinds of limits, not just recommend them.
How Upper Payment Limits Work
An upper payment limit doesn't mean the drug's list price disappears. Think of it as a hard cap on reimbursement. If a plan is required to reimburse a pharmacy for Ozempic, it cannot be forced to pay above that capped rate.
For patients, the real-world effect depends on how your specific insurance plan is structured, whether you're on Medicaid, a state employee plan, or a commercial policy.
Who Benefits Most From This Decision
Not every Ozempic patient in Maryland will feel the same impact right away. The biggest beneficiaries of this type of upper payment limit tend to fall into a few categories.
Medicaid enrollees in Maryland are likely to see the most direct benefit. State Medicaid programs are squarely within the MDAB's jurisdiction, meaning the cap applies to what the state pays pharmacies and pharmacy benefit managers on behalf of those patients.
State employees and retirees on Maryland's public employee health plans may also benefit, since those plans operate under state oversight.
Commercially insured patients are in a murkier position. Private insurance companies aren't always bound by state upper payment limits in the same way, especially if they operate under federal ERISA rules (which govern most large employer plans). Your savings may be indirect, or they may not materialize at all until your plan renegotiates contracts.
Cash-pay patients are largely unaffected by this specific action, since they're not going through a payer that's subject to the cap.
What This Means for Ozempic's List Price
To be clear, this decision does not change Ozempic's list price at the pharmacy counter. Novo Nordisk sets that price, and it remains roughly $900 to $1,000 per month without insurance or a coupon.
What the Maryland ruling changes is how much certain payers have to reimburse. In theory, this pressure could push Novo Nordisk to negotiate lower net prices with Maryland-regulated plans, which could eventually trickle down to patients through lower copays or reduced cost-sharing.
But that trickle-down effect is not guaranteed, and it doesn't happen overnight.
The Rebate System Complicates Things
One reason drug pricing is so confusing is that the sticker price is rarely what anyone actually pays. Pharmaceutical manufacturers offer rebates to insurance companies and pharmacy benefit managers behind the scenes.
When a state caps the upper payment limit, it's working within this murky rebate system. The actual savings passed on to patients depend on how plans respond to the new cap, how aggressively they renegotiate, and whether cost savings are passed along rather than absorbed.
Why Maryland Is Being Watched Closely
Maryland isn't the first state to create a drug affordability board, but it's among the most active in actually using its authority to set binding payment limits. Colorado, Washington, and several other states have similar bodies, but enforcement varies widely.
The Ozempic decision puts Maryland at the front of what may become a national trend. GLP-1 medications like semaglutide and tirzepatide are now among the highest-cost drug categories in the United States, driven by both high list prices and explosive demand.
If Maryland's approach produces measurable savings for state payers, expect other states to accelerate their own affordability efforts. Patients in states like California, New York, and Illinois may see similar board actions within the next few years.
Federal Action Remains Slow
At the federal level, the Inflation Reduction Act gave Medicare limited authority to negotiate drug prices, but GLP-1 medications used primarily for weight loss have faced specific coverage and negotiation hurdles. State-level action like Maryland's is filling a gap that federal policy hasn't fully addressed.
What Ozempic Costs Right Now Without a Cap
For context, here's a snapshot of what patients typically pay for Ozempic and its closest GLP-1 counterparts across different payment situations.
These prices reflect general market conditions as of mid-2025. Prices may vary by pharmacy, location, and plan.
What to Do If You Live Outside Maryland
If you're reading this from Ohio, Texas, Florida, or anywhere outside Maryland, this ruling doesn't directly change your costs today. But it does signal that the tide may be turning, and there are steps you can take now.
Use Manufacturer Savings Programs
Both Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro) offer savings cards and copay assistance programs. These can dramatically reduce your out-of-pocket cost, often to $25 or less per month if you have commercial insurance and meet eligibility criteria. Check the GLP-1 Coupons page for current offers.
Compare Telehealth Providers
Cash-pay pricing varies widely by provider. Some telehealth platforms and weight loss clinics offer compounded semaglutide or tirzepatide at a fraction of brand-name prices. Others have negotiated better rates through specific pharmacy networks. Comparing best providers before you commit can save you hundreds of dollars per month.
Ask About Medicaid or ACA Plan Coverage
If you're uninsured or underinsured, Medicaid expansion and ACA marketplace plans sometimes cover GLP-1 medications for qualifying diagnoses like Type 2 diabetes. Coverage for obesity treatment specifically is more limited but growing. Ask your prescriber whether your diagnosis could support a covered prescription.
The Bigger Picture for GLP-1 Affordability
Maryland's decision is one piece of a larger affordability puzzle. GLP-1 medications work. The clinical evidence for semaglutide and tirzepatide in both diabetes management and weight loss is substantial. The barrier isn't efficacy. It's access and cost.
State affordability boards, federal negotiation, manufacturer assistance programs, compounding pharmacies, and telehealth pricing competition are all part of the same ecosystem. No single lever solves the problem alone.
What this Maryland ruling does is legitimize the idea that governments can and should act on drug pricing, particularly for medications that have become near-essential for millions of patients managing chronic conditions.
No waiting list. No insurance needed.
Frequently Asked Questions
Does the Maryland drug price cap lower Ozempic's cost at the pharmacy for all patients?
Not directly. The upper payment limit set by Maryland's Drug Affordability Board applies to what certain payers, primarily Medicaid and state employee plans, can be required to reimburse. If you pay cash or have commercial insurance, you may not see an immediate change at the pharmacy counter.
What is the Maryland Drug Affordability Board (MDAB)?
The MDAB is a state agency in Maryland authorized to review the cost of prescription drugs and set upper payment limits when those costs are deemed unaffordable. It's one of the few state bodies in the U.S. with actual enforcement power over drug reimbursement rates.
Will other states follow Maryland in capping Ozempic prices?
It's likely that other states with drug affordability boards, including Colorado, Washington, and others, will watch Maryland's outcome closely. If the cap produces meaningful savings, similar actions in other states could follow within the next one to three years.
Does this affect Wegovy or Mounjaro pricing too?
This specific ruling targets Ozempic (semaglutide). However, as states build frameworks for capping drug payments, other high-cost GLP-1 medications like Wegovy and Mounjaro could become targets for similar actions in the future.
How can I lower my Ozempic cost right now if I don't live in Maryland?
Manufacturer savings cards, telehealth provider comparisons, and GLP-1 coupon programs are your best tools today. Novo Nordisk's savings program can reduce Ozempic to as little as $25/month for eligible commercially insured patients. Compounded semaglutide through certain telehealth providers may also be significantly cheaper.
Does Medicaid cover Ozempic for weight loss?
Coverage depends on your state and the reason for prescribing. Ozempic is FDA-approved for Type 2 diabetes, and most state Medicaid programs cover it for that indication. Coverage for weight loss specifically using Wegovy is more limited and varies significantly by state.